The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Open accessAbstract
BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This observation is therefore in accordance with recent clinical trials showing that antifibrotic therapies are effective in progressive fibrotic interstitial lung diseases other than IPF [20,26,27].”
In the citing paper
“nintedanib has also now been approved for systemic sclerosis (SSc)-associated ILD (SSc-ILD), based on the positive outcome of Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (Distler et al., 2019).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Distler et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationvan den Hoogen, F. H. J., Khanna, D., Fransen, J., Johnson, S. R., Baron, M. G., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,881
Self-citationThe St George's Respiratory Questionnaire
Jones, P., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,729
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial Lung Disease in Systemic Sclerosis
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J. C., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,249
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J. G., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,077
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C. P., Farge, D., Kowal‐Bielecka, O., Müller‐Ladner, U., Bocelli‐Tyndall, C., & Matucci‐Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 927
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Erre, G. L., Sebastiani, M., Fenu, M. A., Zinellu, A., Floris, A., Cavagna, L., Renzoni, E. A., Manfredi, A., Passiu, G., Woodman, R. J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082560 · Cited by 22
Sugino, K., Ono, H., Shimizu, H., Kurosawa, T., Matsumoto, K., Ando, M., Mori, K., Tsuboi, E., Homma, S. A., & Kishi, K. (2020) · ERJ Open Research · doi:10.1183/23120541.00196-2020 · Cited by 25
Treatment Initiation in Patients with Interstitial Lung Disease in Canada
Assayag, D., Garlick, K., Johannson, K. A., Fell, C. D., Kolb, M. R. J., Cox, G., Hambly, N., Manganas, H., Morisset, J., Fisher, J. H., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202009-1122oc · Cited by 22
Khor, Y. H., Goh, N. S. L., Wong, A. W., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M. R. J., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202108-980oc · Cited by 23
The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential
Kim, S., Park, H. J., & Lee, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416154 · Cited by 23
Ayoglu, B., Donato, M., Furst, D. E., Crofford, L. J., Goldmuntz, E. A., Keyes-Elstein, L., James, J. A., Macwana, S., Mayes, M. D., McSweeney, P. A., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2021-221926 · Cited by 22
Self-citationKuwana, M., Bando, M., Kawahito, Y., Sato, S., Suda, T., Kondoh, Y., & Collaborators, T. C.-I. D. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2176303 · Cited by 22
Self-citationWalking the path of treatable traits in interstitial lung diseases
Amati, F., Spagnolo, P., Ryerson, C. J., Oldham, J. M., Gramegna, A., Stainer, A., Mantero, M., Sverzellati, N., Lacedonia, D., Richeldi, L., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02554-8 · Cited by 22
Connective tissue disease-associated interstitial lung disease
Storrer, K. M., Müller, C. D. S., Pessoa, M. C. D. A., & Pereira, C. A. D. C. (2024) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20230132 · Cited by 23
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update
Wongkarnjana, A., Yanagihara, T., & Kolb, M. R. J. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1673733 · Cited by 23
Familial Interstitial Lung Disease
Kropski, J. A. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1708054 · Cited by 22
Nawata, T., Shirai, Y., Suzuki, M., & Kuwana, M. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa322 · Cited by 22
Self-citationMoll, S. A., Platenburg, M. G. J. P., Platteel, A. C. M., Vorselaars, A. D. M., Bonás, M. J., Roodenburg-Benschop, C., Meek, B., van Moorsel, C. H. M., & Grutters, J. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092944 · Cited by 23
Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development
Pieri, A. D., Korman, B. D., Jüngel, A., & Wuertz‐Kozak, K. (2021) · Advanced Biology · doi:10.1002/adbi.202000168 · Cited by 25
PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis
Kronborg-White, S. B., Madsen, L. B., Bendstrup, E. M., & Poletti, V. E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235562 · Cited by 24
Aringer, M., Distler, O., Hoffmann‐Vold, A., Kuwana, M., Prosch, H., & Volkmann, E. R. (2024) · RMD Open · doi:10.1136/rmdopen-2024-004704 · Cited by 21
Self-citationBoyle, N., Miller, J., Quinn, S., Maguire, J., Fabre, A., Morrisroe, K., Murphy, D. J., & McCarthy, C. (2025) · Breathe · doi:10.1183/20734735.0171-2024 · Cited by 23
Ciaffi, J., van Leeuwen, N. M., Boonstra, M., Kroft, L. J. M., Schouffoer, A. A., Ninaber, M. K., Huizinga, T. W. J., & Vries-Bouwstra, J. K. D. (2020) · Arthritis Care & Research · doi:10.1002/acr.24451 · Cited by 21
Jee, A. S., Parker, M. J. S., Bleasel, J. F., Troy, L. K., Lau, E., Jo, H. E., Teoh, A. K. Y., Adelstein, S., Webster, S. E., & Corte, T. J. (2021) · Respiration · doi:10.1159/000515396 · Cited by 21
Wilfong, E. M., & Aggarwal, R. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211060907 · Cited by 21
Chronic Lung Allograft Dysfunction
Venado, A. E., Kukreja, J., & Greenland, J. R. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2021.11.004 · Cited by 21
The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study
Saiphoklang, N., Patanayindee, P., & Ruchiwit, P. (2022) · Critical Care Research and Practice · doi:10.1155/2022/9972846 · Cited by 21
Yin, Y., Liu, S., Li, P., Luo, J., Liu, H., & Wu, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114543 · Cited by 21
Prognostic value of automated assessment of interstitial lung disease on CT in systemic sclerosis
Gall, A. L., Hoang-Thi, T.-N., Porcher, R., Dunogué, B., BEREZNE, A., Guillevin, L., Guern, V. L., Cohen, P., Chaigne, B., London, J., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead164 · Cited by 21
Turgeon, D. K., Balter, M. S., & Pagnoux, C. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000979 · Cited by 21
Immunoglobulins in systemic sclerosis management. A large multicenter experience
Tandaipan, J. L., del Castillo, A. G., Simeón‐Aznar, C. P., Carreira, P. E., de la Puente, C., Narváez, J., Lluch, J., Rubio‐Rivas, M., Sancho, J. J. A., Bonilla, G., et al. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103441 · Cited by 21
Zhao, R., Xie, B., Wang, X., Zhang, X., Ren, Y., Wang, C., & Dai, H. (2024) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2024.102287 · Cited by 22
Watanabe, S., Yomono, K., Yamamoto, S., Suzuki, M., Gono, T., & Kuwana, M. (2024) · Modern Rheumatology · doi:10.1093/mr/roae053 · Cited by 22
Self-citationAntifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances
Naqvi, M., Hannah, J. R., Lawrence, A., Myall, K. J., West, A., & Chaudhuri, N. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2375420 · Cited by 22
Chen, Y., Gong, Y., Shi, M., Zhu, H., Tang, Y., Huang, D., Wang, W., Shi, C., Xia, X., Zhang, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.11.027 · Cited by 21
Singh, V., Singh, S., Sharma, B., Bairwa, M. L., Gothi, D., Desai, U. D., Joshi, J. M., Talwar, D., Singh, A., Dhar, R., et al. (2020) · Lung India · doi:10.4103/lungindia.lungindia_275_20 · Cited by 22
Self-citationAzuma, A., Chung, L. S., Behera, D., Chung, M. P., Kondoh, Y., Ogura, T., Okamoto, M., Swarnakar, R., Zeng, X., Zou, H., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.10.005 · Cited by 21
Self-citationSerum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
Guiot, J., Njock, M., André, B., Gester, F., Henket, M. A., de Seny, D., Moermans, C., Malaise, M., & Louis, R. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-90333-0 · Cited by 21
Ground glass and fibrotic change in children with surfactant protein C dysfunction mutations
DeBoer, E. M., Liptzin, D. R., Humphries, S. M., Lynch, D. A., Robison, K., Galambos, C., Dishop, M. K., Deterding, R. R., & Weinman, J. P. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25356 · Cited by 21
Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases
Castelino, F. V., & Moua, T. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11253 · Cited by 22
Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline
Nagy, A., Nagy, T., Kolonics-Farkas, A. M., Eszes, N., Vincze, K., Bárczi, E., Tárnoki, Á. D., Tárnoki, D. L., Nagy, G. M., Kiss, E. V., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.778649 · Cited by 21
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Bonella, F., Cottin, V., Valenzuela, C., Wijsenbeek, M. S., Voß, F., Rohr, K. B., Stowasser, S., & Maher, T. M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02145-x · Cited by 21
Self-citationMacrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease
Lee, S.-C., Huang, C.-H., Oyang, Y.-J., Huang, H., & Juan, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05403-4 · Cited by 20
Diagnosis and Management of Fibrotic Interstitial Lung Diseases
Collins, B. F., & Luppi, F. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.008 · Cited by 21
The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis
Kobayashi, S., Nagafuchi, Y., Shoda, H., & Fujio, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.900638 · Cited by 20
Kacprzak, A., Tomkowski, W. Z., & Szturmowicz, M. (2023) · Diagnostics · doi:10.3390/diagnostics13142354 · Cited by 20
COPA Syndrome from Diagnosis to Treatment
Simchoni, N., Vogel, T. P., & Shum, A. K. (2023) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2023.06.005 · Cited by 22
Recent Advances in Treatment of Systemic Sclerosis and Morphea
Teske, N. M., & Fett, N. M. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00831-2 · Cited by 20
D’Agnano, V., Mariniello, D. F., Ruotolo, M., Quarcio, G., Moriello, A., Conte, S., Sorrentino, A., Zamparelli, S. S., Bianco, A., & Perrotta, F. (2024) · Life · doi:10.3390/life14020229 · Cited by 21
Soldano, S., Smith, V. M., Montagna, P., Gotelli, E., Campitiello, R., Pizzorni, C., Paolino, S., Sulli, A., Cere, A., & Cutolo, M. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03308-7 · Cited by 20
Upregulation of GPX4 drives ferroptosis resistance in scleroderma skin fibroblasts
Zhang, F., Xiao, Y., Huang, Z., Wang, Y., Wan, W., Zou, H., Wang, B., Qiu, X., & Yang, X. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.05.013 · Cited by 20
Kondoh, Y., Bando, M., Kawahito, Y., Sato, S., Suda, T., & Kuwana, M. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2374910 · Cited by 21
Self-citationvan den Hoogen, L. L., & van Laar, J. M. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101485 · Cited by 21
The future of treatment in systemic sclerosis: can we design better trials?
Pope, J. E. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30010-2 · Cited by 20
Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
Boerner, E. B., Cuyás, M. C., Theegarten, D., Ohshimo, S., Costabel, U., & Bonella, F. (2020) · Respiration · doi:10.1159/000508540 · Cited by 20
Yamagata, A., Arita, M., Tachibana, H., Tokioka, F., Sugimoto, C., Sumikawa, H., Tanaka, T., Yasui, H., Fujisawa, T., Nakamura, Y., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01726-8 · Cited by 20
Management of Connective Tissue Disease-Associated Interstitial Lung Disease
Kawano-Dourado, L. B., & Lee, J. S. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.010 · Cited by 21
Antibody-based therapies for idiopathic pulmonary fibrosis
Sgalla, G., Flore, M., Siciliano, M., & Richeldi, L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1735346 · Cited by 22
Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date
Ntolios, P., Steiropoulos, P., Karpathiou, G., Anevlavis, S., Karampitsakos, Τ., Bouros, E., Froudarakis, Μ. E., Bouros, D. E., & Tzouvelekis, A. (2020) · BioDrugs · doi:10.1007/s40259-020-00437-8 · Cited by 19
Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases
Kershaw, C. D., Batra, K., Torrealba, J. R., & Terada, L. S. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106400 · Cited by 21
Gastrointestinal symptom severity and progression in systemic sclerosis
van Leeuwen, N. M., Boonstra, M., Fretheim, H., Brunborg, C., Midtvedt, Ø., Garen, T., Molberg, Ø., Huizinga, T. W. J., Vries-Bouwstra, J. K. D., & Hoffman‐Vold, A. (2022) · Rheumatology · doi:10.1093/rheumatology/keac118 · Cited by 19
Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature
Dolivo, D. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02194-3 · Cited by 19
Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
Raschi, E., Fusaroli, M., Gatti, M., Caraceni, P., Poluzzi, E., & Ponti, F. D. (2022) · Pharmaceuticals · doi:10.3390/ph15050645 · Cited by 20
Kuwana, M., Avouac, J., Hoffmann‐Vold, A., Smith, V. M., Toenges, G., Alves, M., & Distler, O. (2024) · RMD Open · doi:10.1136/rmdopen-2024-004240 · Cited by 19
Self-citationImaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Chung, J. H., Walker, C. M., & Hobbs, S. (2020) · Journal of Visualized Experiments · doi:10.3791/60300 · Cited by 19
Kase, K., Watanabe, S., Saeki, K., Waseda, Y., Takato, H., Ichikawa, Y., Murata, A., Yasui, M., Ohkura, N., Hara, J., et al. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-2596 · Cited by 19
Lazzaroni, M. G., Piantoni, S., Angeli, F., Bertocchi, S., Franceschini, F., & Airó, P. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08929-x · Cited by 19
Foeldvari, I., & Torok, K. S. (2021) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2021.101688 · Cited by 19
Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanisms
Doskaliuk, B., Zaiats, L., Yatsyshyn, R., Gerych, P., Cherniuk, N., & Zimba, O. (2020) · Rheumatology International · doi:10.1007/s00296-020-04658-6 · Cited by 19
Xu, L., Wang, F., & Luo, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1019915 · Cited by 18
Nashatyreva, M. S., Николаевна, Т. И., Chernyak, B. A., & Avdeev, S. N. (2023) · Life · doi:10.3390/life13010212 · Cited by 18
Kreuter, M., Bendstrup, E. M., Jouneau, S., Maher, T. M., Inoue, Y., Miede, C., Lievens, D., & Crestani, B. (2023) · Respiratory Research · doi:10.1186/s12931-023-02371-z · Cited by 19
Self-citationRole of Extracellular Vesicles in the Propagation of Lung Fibrosis in Systemic Sclerosis
Mouawad, J. E., Sanderson, M., Sharma, S., Helke, K. L., Pilewski, J. M., Nadig, S. N., & Feghali‐Bostwick, C. A. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42638 · Cited by 20
Personalized medicine in sarcoidosis: unravelling biomarkers for targeted care
Francesqui, J., Marrades, P., & Sellarés, J. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000985 · Cited by 18
Bhandari, S., Bhandari, S., & Bhandari, S. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000891 · Cited by 19
Matsuda, S., Kotani, T., Okazaki, A., Nishioka, D., Watanabe, R., Gon, T., Manabe, A., Shoji, M., Kadoba, K., Hiwa, R., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead444 · Cited by 18
The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases
Luppi, F., Manfredi, A., Faverio, P., Andersen, M. B., Bono, F., Pagni, F., Salvarani, C., Bendstrup, E. M., & Sebastiani, M. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02783-z · Cited by 18
ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
Durheim, M. T., Hoffmann‐Vold, A., Eagan, T., Hovden, A., Lund, M. B., Bjerke, G., Birring, S. S., Jonassen, T. M., Johansen, O. E., & Sjåheim, T. (2020) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000598 · Cited by 18
Song, Y. C., Lee, S. E., Jin, Y., Park, H. W., Chun, K., & Lee, H. (2020) · PubMed · doi:10.14348/molcells.2020.0118 · Cited by 19
Davidsen, J. R., Miedema, J., Wuyts, W. A., Kilpeläinen, M., Papiris, S. A., Manali, E. D., Cordeiro, C. R., Morais, A., Pérez, M., Asijee, G. M., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01541-5 · Cited by 18
Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
Bos, S., Sadeleer, L. D., Vanstapel, A., Beeckmans, H., Sacreas, A., Yserbyt, J., Wuyts, W. A., & Vos, R. (2021) · European Respiratory Review · doi:10.1183/16000617.0050-2021 · Cited by 20
Wijsenbeek, M. S., Bendstrup, E. M., Valenzuela, C., Henry, M. T., Moor, C. C., Jouneau, S., Fois, A. G., Moran‐Mendoza, O., Anees, S., Mirt, M., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01790-y · Cited by 18
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Schmid, U., Weber, B., Sarr, C., & Freiwald, M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01598-0 · Cited by 18
Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98161-y · Cited by 19
Treatment of systemic sclerosis
Thoreau, B., Chaigne, B., Renaud, A., & Mouthon, L. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104088 · Cited by 18
Komatsu, M., Yamamoto, H., Ichiyama, T., Kawakami, S., Uehara, T., Yoshikawa, Y., Kitaguchi, Y., Ushiki, A., Yasuo, M., & Hanaoka, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262795 · Cited by 18
Kidney Involvement in Systemic Sclerosis
Reggiani, F., Moroni, G. L., & Ponticelli, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071123 · Cited by 18
Ruaro, B., Gandin, I., Pozzan, R., Tavano, S., Bozzi, C., Hughes, M., Kodric, M., Cifaldi, R., Lerda, S., Confalonieri, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020307 · Cited by 19
Frye, B. C., Rump, I. C., Uhlmann, A., Schubach, F., Ihorst, G., Grimbacher, B., Zissel, G., & Quernheim, J. M. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100575 · Cited by 18
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Yumura, M., Nagano, T., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173987 · Cited by 17
Aronson, K. I., & Suzuki, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.745908 · Cited by 17
Pugnet, G., Petermann, A., Collot, S., Otal, P., Lansiaux, P., Abdallah, N. A., Lorillon, G., Resche‐Rigon, M., Borel, C., Marjanovic, Z., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac319 · Cited by 17
Roofeh, D., Brown, K. M., Kazerooni, E. A., Tashkin, D. P., Assassi, S., Martínez, F. J., Wells, A. U., Raghu, G., Denton, C. P., Chung, L. S., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac557 · Cited by 17
Self-citationPan, L., Meng, F., Wang, W., Wang, X.-H., Shen, H., Bao, P., Kang, J., & Kong, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1072612 · Cited by 17
Yamano, Y., Kataoka, K., Takei, R., Sasano, H., Yokoyama, T., Matsuda, T., Kimura, T., Mori, Y., Furukawa, T., Fukuoka, J., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.01.007 · Cited by 18
Joung, K.-I., Park, H., Park, S.-Y., Shin, J., & Kim, Y. H. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02373-z · Cited by 17
Yamakawa, H., Sato, S., Ohta, H., Kusano, K., Kawabe, R., Oba, T., Uzuka, C., Sasaki, H., Akasaka, K., Amano, M., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.04.011 · Cited by 18
A Review of Myositis-Associated Interstitial Lung Disease
Kannappan, R., Kumar, R., Cichelli, K., & Brent, L. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144055 · Cited by 17
ADAM Metallopeptidase domain 19 promotes skin fibrosis in systemic sclerosis via neuregulin-1
Meng, Q., Bao, D., Liu, S., Huang, J., Guo, M., Dai, B., Ding, L., Xie, S., Meng, M., Lv, C., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01047-8 · Cited by 18
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 20
Sekine, A., Wasamoto, S., Hagiwara, E., Yamakawa, H., Ikeda, S., Okabayashi, H., Oda, T., Okuda, R., Kitamura, H., Baba, T., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.10.002 · Cited by 19
The Treatment of Lung Involvement in Systemic Sclerosis
Ruaro, B., Confalonieri, M., Matucci‐Cerinic, M., Salton, F., Confalonieri, P., Santagiuliana, M., Citton, G. M., Baratella, E., & Bruni, C. (2021) · Pharmaceuticals · doi:10.3390/ph14020154 · Cited by 17
Spierings, J., Chiu, Y., Voortman, M., & van Laar, J. M. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211035196 · Cited by 17
Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
Albera, C., Verri, G., Sciarrone, F., Sitia, E., Mangiapia, M., & Solidoro, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091237 · Cited by 17
Dysregulation of Type I Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?
Wu, M., & Assassi, S. (2021) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-021-00188-9 · Cited by 17
Metadata
- Authors
- Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., Clerisme-Beaty, E., Stowasser, S., Tetzlaff, K., Kuwana, M., & Maher, T. M.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-27
- Volume
- 380
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945521814
- Cited by
- 1,647
- References
- 36
- Citations by year
- 2026: 139 · 2025: 203 · 2024: 215 · 2023: 231 · 2022: 243 · 2021: 299 · 2020: 247 · 2019: 68
- FWCI
- 157.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tyrosine kinase inhibitors, antifibrotic therapy, forced vital capacity decline, pulmonary fibrosis, diffuse cutaneous systemic sclerosis, skin involvement, quality of life, diarrhea, adverse events, mycophenolate, modified Rodnan skin score, St George's Respiratory Questionnaire
- MeSH terms
- Administration, Oral, Adult, Diarrhea, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Scleroderma, Systemic, Vital Capacity, Lung Diseases, Interstitial, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
